IGF-1R targeting in cancer – does sub-cellular localization matter?
Abstract The insulin-like growth factor receptor (IGF-1R) was among the most intensively pursued kinase targets in oncology. However, even after a slew of small-molecule and antibody therapeutics reached clinical trials for a range of solid tumors, the initial promise remains unfulfilled. Mechanisms...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-023-02850-7 |
| _version_ | 1797555678943903744 |
|---|---|
| author | Upendra K. Soni Liam Jenny Rashmi S. Hegde |
| author_facet | Upendra K. Soni Liam Jenny Rashmi S. Hegde |
| author_sort | Upendra K. Soni |
| collection | DOAJ |
| description | Abstract The insulin-like growth factor receptor (IGF-1R) was among the most intensively pursued kinase targets in oncology. However, even after a slew of small-molecule and antibody therapeutics reached clinical trials for a range of solid tumors, the initial promise remains unfulfilled. Mechanisms of resistance to, and toxicities resulting from, IGF-1R-targeted drugs are well-catalogued, and there is general appreciation of the fact that a lack of biomarker-based patient stratification was a limitation of previous clinical trials. But no next-generation therapeutic strategies have yet successfully exploited this understanding in the clinic. Currently there is emerging interest in re-visiting IGF-1R targeted therapeutics in combination-treatment protocols with predictive biomarker-driven patient-stratification. One such biomarker that emerged from early clinical trials is the sub-cellular localization of IGF-1R. After providing some background on IGF-1R, its drugging history, and the trials that led to the termination of drug development for this target, we look more deeply into the correlation between sub-cellular localization of IGF-1R and susceptibility to various classes of IGF-1R - targeted agents. |
| first_indexed | 2024-03-10T16:50:56Z |
| format | Article |
| id | doaj.art-99850203b21a4405a66107136855d0f2 |
| institution | Directory Open Access Journal |
| issn | 1756-9966 |
| language | English |
| last_indexed | 2024-03-10T16:50:56Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj.art-99850203b21a4405a66107136855d0f22023-11-20T11:18:05ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662023-10-0142111210.1186/s13046-023-02850-7IGF-1R targeting in cancer – does sub-cellular localization matter?Upendra K. Soni0Liam Jenny1Rashmi S. Hegde2Division of Developmental Biology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of MedicineDivision of Developmental Biology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of MedicineDivision of Developmental Biology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of MedicineAbstract The insulin-like growth factor receptor (IGF-1R) was among the most intensively pursued kinase targets in oncology. However, even after a slew of small-molecule and antibody therapeutics reached clinical trials for a range of solid tumors, the initial promise remains unfulfilled. Mechanisms of resistance to, and toxicities resulting from, IGF-1R-targeted drugs are well-catalogued, and there is general appreciation of the fact that a lack of biomarker-based patient stratification was a limitation of previous clinical trials. But no next-generation therapeutic strategies have yet successfully exploited this understanding in the clinic. Currently there is emerging interest in re-visiting IGF-1R targeted therapeutics in combination-treatment protocols with predictive biomarker-driven patient-stratification. One such biomarker that emerged from early clinical trials is the sub-cellular localization of IGF-1R. After providing some background on IGF-1R, its drugging history, and the trials that led to the termination of drug development for this target, we look more deeply into the correlation between sub-cellular localization of IGF-1R and susceptibility to various classes of IGF-1R - targeted agents.https://doi.org/10.1186/s13046-023-02850-7IGF-1RTherapeuticscancerSarcomaBiomarkersCombination therapy |
| spellingShingle | Upendra K. Soni Liam Jenny Rashmi S. Hegde IGF-1R targeting in cancer – does sub-cellular localization matter? Journal of Experimental & Clinical Cancer Research IGF-1R Therapeutics cancer Sarcoma Biomarkers Combination therapy |
| title | IGF-1R targeting in cancer – does sub-cellular localization matter? |
| title_full | IGF-1R targeting in cancer – does sub-cellular localization matter? |
| title_fullStr | IGF-1R targeting in cancer – does sub-cellular localization matter? |
| title_full_unstemmed | IGF-1R targeting in cancer – does sub-cellular localization matter? |
| title_short | IGF-1R targeting in cancer – does sub-cellular localization matter? |
| title_sort | igf 1r targeting in cancer does sub cellular localization matter |
| topic | IGF-1R Therapeutics cancer Sarcoma Biomarkers Combination therapy |
| url | https://doi.org/10.1186/s13046-023-02850-7 |
| work_keys_str_mv | AT upendraksoni igf1rtargetingincancerdoessubcellularlocalizationmatter AT liamjenny igf1rtargetingincancerdoessubcellularlocalizationmatter AT rashmishegde igf1rtargetingincancerdoessubcellularlocalizationmatter |